Research Analysts Set Expectations for TSE:FRX Q3 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.17 per share for the quarter, down from their prior estimate of $0.26. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.22 EPS, Q3 2027 earnings at $0.36 EPS, Q4 2027 earnings at $0.42 EPS and FY2027 earnings at $1.33 EPS.

Separately, B. Riley Financial raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company has an average rating of “Strong Buy”.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$8.33 on Tuesday. Fennec Pharmaceuticals has a 52-week low of C$7.02 and a 52-week high of C$13.83. The company has a market capitalization of C$284.58 million, a P/E ratio of -23.80 and a beta of 3.01. The company has a 50 day moving average of C$10.57 and a 200 day moving average of C$11.14.

Insider Activity

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov acquired 15,598 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were acquired at an average price of C$3.37 per share, for a total transaction of C$52,565.26. Following the acquisition, the director owned 2,719,643 shares in the company, valued at C$9,165,196.91. The trade was a 0.58% increase in their position. Corporate insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.